Pub Date : 2021-03-03DOI: 10.19080/IJOPRS.2021.04.555646
A. Alsaeedi
Background: Tocilizumab, through the blocking of interleukin-6 receptors, is hypothesized to be effective in the treatment of severe coronavirus disease 2019 (COVID-19). However, data on tocilizumab use in this setting is conflicting. Objective: To evaluate the effect of tocilizumab treatment on the outcomes of patients with severe COVID-19 pneumonia. Methods: A retrospective case-control study including 168 patients hospitalized with severe COVID-19 pneumonia at Al-Jahra hospital, Kuwait, from April 1st to June 30th. All patients received standard of care treatment. Patients in the tocilizumab group received tocilizumab infusion. The primary outcomes were death, need for mechanical ventilation and the proportion of patients with clinical improvement. The incidence of adverse events was monitored. Results: Need for mechanical ventilation was higher in the tocilizumab group (48% vs. 24.3%, p=0.002). Clinical improvement was lower (54.1% vs. 71.4%) and number of deaths were higher (29.6% vs. 10%) in the tocilizumab group (p=0.009). There was no difference in the mean survival time between tocilizumab and control group (17.7 days vs. 19.2 days). There was no significant difference between the two groups regarding the incidence of infections (6.1% vs. 2.9%, p=0.471). Conclusion: Our results suggest that use of tocilizumab in severe COVID-19 pneumonia does not provide clinical or mortality benefit. However, further research is needed to determine the ideal utilization of tocilizumab in the setting of severe COVID-19 disease.
背景:托珠单抗通过阻断白细胞介素-6受体，被推测可有效治疗2019年严重冠状病毒病(COVID-19)。然而，托珠单抗在这种情况下的使用数据是相互矛盾的。目的:评价托珠单抗治疗对重症COVID-19肺炎患者预后的影响。方法:对4月1日至6月30日在科威特Al-Jahra医院收治的168例重症COVID-19肺炎患者进行回顾性病例对照研究。所有患者均接受标准护理治疗。托珠单抗组患者接受托珠单抗输注。主要结局为死亡、机械通气需求和临床改善患者比例。监测不良事件的发生率。结果:托珠单抗组机械通气需求较高(48% vs. 24.3%， p=0.002)。托珠单抗组的临床改善较低(54.1%对71.4%)，死亡人数较高(29.6%对10%)(p=0.009)。托珠单抗组和对照组的平均生存时间没有差异(17.7天对19.2天)。两组感染发生率无显著差异(6.1% vs. 2.9%， p=0.471)。结论:我们的研究结果表明，在重症COVID-19肺炎中使用托珠单抗并没有提供临床或死亡率方面的益处。然而，需要进一步的研究来确定托珠单抗在严重COVID-19疾病背景下的理想应用。
{"title":"Tocilizumab Treatment for Hospitalized Patients with Severe Covid-19 Pneumonia: A Retrospective Case-Control Study","authors":"A. Alsaeedi","doi":"10.19080/IJOPRS.2021.04.555646","DOIUrl":"https://doi.org/10.19080/IJOPRS.2021.04.555646","url":null,"abstract":"Background: Tocilizumab, through the blocking of interleukin-6 receptors, is hypothesized to be effective in the treatment of severe coronavirus disease 2019 (COVID-19). However, data on tocilizumab use in this setting is conflicting. Objective: To evaluate the effect of tocilizumab treatment on the outcomes of patients with severe COVID-19 pneumonia. Methods: A retrospective case-control study including 168 patients hospitalized with severe COVID-19 pneumonia at Al-Jahra hospital, Kuwait, from April 1st to June 30th. All patients received standard of care treatment. Patients in the tocilizumab group received tocilizumab infusion. The primary outcomes were death, need for mechanical ventilation and the proportion of patients with clinical improvement. The incidence of adverse events was monitored. Results: Need for mechanical ventilation was higher in the tocilizumab group (48% vs. 24.3%, p=0.002). Clinical improvement was lower (54.1% vs. 71.4%) and number of deaths were higher (29.6% vs. 10%) in the tocilizumab group (p=0.009). There was no difference in the mean survival time between tocilizumab and control group (17.7 days vs. 19.2 days). There was no significant difference between the two groups regarding the incidence of infections (6.1% vs. 2.9%, p=0.471). Conclusion: Our results suggest that use of tocilizumab in severe COVID-19 pneumonia does not provide clinical or mortality benefit. However, further research is needed to determine the ideal utilization of tocilizumab in the setting of severe COVID-19 disease.","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121471800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-15DOI: 10.19080/IJOPRS.2020.04.555645
Y. Spanidis
{"title":"Interstitial Pneumonitis Due to Janus Kinase Inhibitor Baricitinib in a Rheumatic Arthritis Patient","authors":"Y. Spanidis","doi":"10.19080/IJOPRS.2020.04.555645","DOIUrl":"https://doi.org/10.19080/IJOPRS.2020.04.555645","url":null,"abstract":"","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"154 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116696641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-11DOI: 10.19080/IJOPRS.2020.04.555644
K. Alawam
In Recent times, there is remarkable worldwide increase in the use of electronic nicotine products and also electronic nicotine delivery system [1]. Vaping is the act of inhaling and exhaling the aerosol, it refers as a vapor device, the term is used because e-cigarettes do not produce tobacco smoke, but rather than aerosol, often mistaken for water vapor, that actually consists of fine particles. Many of these particles contain varying amounts of toxic chemicals, which have been linked to cancer, as well as respiratory and heart disease. Vaporizer products usually contains of propylene glycol or vegetable glycerin-based liquid with nicotine, flavoring and other chemicals and metals, but not tobacco [2,3].
{"title":"Health Effects of E-Cigarettes with or without Nicotine","authors":"K. Alawam","doi":"10.19080/IJOPRS.2020.04.555644","DOIUrl":"https://doi.org/10.19080/IJOPRS.2020.04.555644","url":null,"abstract":"In Recent times, there is remarkable worldwide increase in the use of electronic nicotine products and also electronic nicotine delivery system [1]. Vaping is the act of inhaling and exhaling the aerosol, it refers as a vapor device, the term is used because e-cigarettes do not produce tobacco smoke, but rather than aerosol, often mistaken for water vapor, that actually consists of fine particles. Many of these particles contain varying amounts of toxic chemicals, which have been linked to cancer, as well as respiratory and heart disease. Vaporizer products usually contains of propylene glycol or vegetable glycerin-based liquid with nicotine, flavoring and other chemicals and metals, but not tobacco [2,3].","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131639896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-03DOI: 10.19080/IJOPRS.2020.04.555643
Meriem Berkchi
and right mainstem bronchus disease the presence of anthracotic in the superior. taken from the back in of a The coexistence of lung cancer and pulmonary tuberculosis is a relatively rare and can be difficult to diagnose. We present the medical observation of a discovery concomitant of these 2 pathologies. This is a 68-year-old patient, a chronic 30 packet smoker weaned 2 years ago, followed for Parkinson’s disease under treatment and presented in a picture of dyspnea associated with productive cough bringing back mucopurulent sputum in a feverish context and whose chest x-ray showed total atelectasis of the left lung. A fibroscopy bronchial examination showed a budding stenosis of the left main bronchus and biopsies of the bud were in favor of adenocarcinoma. A chest CT done as part of the assessment of extension having objectified micronodules in tree bud making suspect a possible pulmonary tuberculosis and which has been confirmed by evidence of AFB in the fluid bronchial aspiration. The patient was put on antibacillary treatment and then referred to the service oncology for oncology treatment. The concomitant association between tuberculosis and neopulmonary disease exists with multiple pathophysiological mechanisms and thus complicates the diagnosis and prognosis.
{"title":"Association with Bronchial Carcinoma and Pulmonary Tuberculosis: About 1 Case","authors":"Meriem Berkchi","doi":"10.19080/IJOPRS.2020.04.555643","DOIUrl":"https://doi.org/10.19080/IJOPRS.2020.04.555643","url":null,"abstract":"and right mainstem bronchus disease the presence of anthracotic in the superior. taken from the back in of a The coexistence of lung cancer and pulmonary tuberculosis is a relatively rare and can be difficult to diagnose. We present the medical observation of a discovery concomitant of these 2 pathologies. This is a 68-year-old patient, a chronic 30 packet smoker weaned 2 years ago, followed for Parkinson’s disease under treatment and presented in a picture of dyspnea associated with productive cough bringing back mucopurulent sputum in a feverish context and whose chest x-ray showed total atelectasis of the left lung. A fibroscopy bronchial examination showed a budding stenosis of the left main bronchus and biopsies of the bud were in favor of adenocarcinoma. A chest CT done as part of the assessment of extension having objectified micronodules in tree bud making suspect a possible pulmonary tuberculosis and which has been confirmed by evidence of AFB in the fluid bronchial aspiration. The patient was put on antibacillary treatment and then referred to the service oncology for oncology treatment. The concomitant association between tuberculosis and neopulmonary disease exists with multiple pathophysiological mechanisms and thus complicates the diagnosis and prognosis.","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126124126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-14DOI: 10.19080/IJOPRS.2020.04.555642
J. Hamacher
A 68 years old rheumatoid arthritis patient received the janus kinase inhibitor baricitinib after a 2.5 years treatment with abatacept. Under abatacept she developed important cough, which was the reason to directly change to baricitinib. Within days cough was much aggravated and baricitinib treatment stopped after two weeks. The cough decreased, and six-week later baricitinib treatment was restarted. Within 14 days cough reappeared and novel exertional dyspnoea and hypoxaemia, aggravated with low exercise, and erythema at the face, neck, upper trunk, volar arms including wrists developed. Clinical findings, a novel restrictive lung function and gas diffusion impairment, and computer tomography were consistent with an acute pneumonitis due to baricitinib treatment. Baricitinib was stopped, and recovery was virtually complete within six weeks. We conclude that a very probable baricitinib pneumonitis occurred. To our knowledge, this is the first published case of this adverse effect in a rheumatoid arthritis patient.
{"title":"Interstitial Pneumonitis Due to Janus Kinase Inhibitor Baricitinib in a Rheumatic Arthritis Patient","authors":"J. Hamacher","doi":"10.19080/IJOPRS.2020.04.555642","DOIUrl":"https://doi.org/10.19080/IJOPRS.2020.04.555642","url":null,"abstract":"A 68 years old rheumatoid arthritis patient received the janus kinase inhibitor baricitinib after a 2.5 years treatment with abatacept. Under abatacept she developed important cough, which was the reason to directly change to baricitinib. Within days cough was much aggravated and baricitinib treatment stopped after two weeks. The cough decreased, and six-week later baricitinib treatment was restarted. Within 14 days cough reappeared and novel exertional dyspnoea and hypoxaemia, aggravated with low exercise, and erythema at the face, neck, upper trunk, volar arms including wrists developed. Clinical findings, a novel restrictive lung function and gas diffusion impairment, and computer tomography were consistent with an acute pneumonitis due to baricitinib treatment. Baricitinib was stopped, and recovery was virtually complete within six weeks. We conclude that a very probable baricitinib pneumonitis occurred. To our knowledge, this is the first published case of this adverse effect in a rheumatoid arthritis patient.","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115728573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-10DOI: 10.19080/ijoprs.2020.04.555641
J. Aviv
{"title":"Covid-19 Era Post Viral Vagal Neuropathy Presenting as Persistent Shortness of Breath with Normal Pulmonary Imaging","authors":"J. Aviv","doi":"10.19080/ijoprs.2020.04.555641","DOIUrl":"https://doi.org/10.19080/ijoprs.2020.04.555641","url":null,"abstract":"","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127086389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-22DOI: 10.19080/IJOPRS.2020.04.555640
A. L. Ribeiro
Muscle strength is a physical capacity that is associated with good health and consequently better quality of life, mental health, among other benefits. Therefore, muscle strength has been indicated as an important marker of mortality Cooper, Kuh, Hardy, & Mortality Review Group [1].
{"title":"Strength and Chronic Obstructive Pulmonary Disease","authors":"A. L. Ribeiro","doi":"10.19080/IJOPRS.2020.04.555640","DOIUrl":"https://doi.org/10.19080/IJOPRS.2020.04.555640","url":null,"abstract":"Muscle strength is a physical capacity that is associated with good health and consequently better quality of life, mental health, among other benefits. Therefore, muscle strength has been indicated as an important marker of mortality Cooper, Kuh, Hardy, & Mortality Review Group [1].","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130499274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-02DOI: 10.19080/ijoprs.2019.04.555637
G. Sarla
Objective: Diabetic feet and toe deformities is commonly associated with diabetes mellitus and neuropathy is the causative factor combined with vasculopathy. In this study we list out various morphological changes which occur in Diabetic foot lesions, the pathophysiology and the management of the deformed toes and feet.
{"title":"Morphological Changes in Diabetic Foot","authors":"G. Sarla","doi":"10.19080/ijoprs.2019.04.555637","DOIUrl":"https://doi.org/10.19080/ijoprs.2019.04.555637","url":null,"abstract":"Objective: Diabetic feet and toe deformities is commonly associated with diabetes mellitus and neuropathy is the causative factor combined with vasculopathy. In this study we list out various morphological changes which occur in Diabetic foot lesions, the pathophysiology and the management of the deformed toes and feet.","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"59 5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124356650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-10DOI: 10.19080/ijoprs.2019.04.555634
F. Griesinger
The Immune-Checkpoint Inhibitor (ICI) therapy that has evolved as a standard of care for stage IV and III is now moving into the early stages. Three studies on ICI-induction therapy in early or locally advanced NSCLC (stages II and III) were presented at ASCO.
{"title":"Highlights of ASCO","authors":"F. Griesinger","doi":"10.19080/ijoprs.2019.04.555634","DOIUrl":"https://doi.org/10.19080/ijoprs.2019.04.555634","url":null,"abstract":"The Immune-Checkpoint Inhibitor (ICI) therapy that has evolved as a standard of care for stage IV and III is now moving into the early stages. Three studies on ICI-induction therapy in early or locally advanced NSCLC (stages II and III) were presented at ASCO.","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"142 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133400794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-10DOI: 10.19080/ijoprs.2019.04.555633
F. Griesinger
Lung cancer ist the most frequent deadly malignant disease in men and the second most deadly malignant disease in women [1]. Two “leap†innovations, the detection of driver mutations in about 25% of patients and the observation that NSCLC is an immune-checkpoint-inhibitor responsive disease leading to a dramatic improvement in ORR, PFS and OS, therapeutic standards in NSCLC have changed dramatically over the past decade [2].
{"title":"Immune-Therapy Standards Of Care","authors":"F. Griesinger","doi":"10.19080/ijoprs.2019.04.555633","DOIUrl":"https://doi.org/10.19080/ijoprs.2019.04.555633","url":null,"abstract":"Lung cancer ist the most frequent deadly malignant disease in men and the second most deadly malignant disease in women [1]. Two “leap†innovations, the detection of driver mutations in about 25% of patients and the observation that NSCLC is an immune-checkpoint-inhibitor responsive disease leading to a dramatic improvement in ORR, PFS and OS, therapeutic standards in NSCLC have changed dramatically over the past decade [2].","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124431888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：